JAKAVI

This brand name is authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug JAKAVI contains one active pharmaceutical ingredient (API):

1	Ruxolitinib UNII 436LRU32H5 - RUXOLITINIB PHOSPHATE
	Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2. These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function.
	Read more about Ruxolitinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JAKAVI Tablet	MPI, EU: SmPC	European Medicines Agency (EU)
JAKAVI Oral solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EJ01	Ruxolitinib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EJ Janus-associated kinase (JAK) inhibitors
Discover more medicines within L01EJ01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10614P, 10615Q, 10616R, 10617T, 10618W, 10619X, 10913J, 10927D
BR	Câmara de Regulação do Mercado de Medicamentos	526516020085601, 526516020085701, 526516020085801, 526520070095707
CA	Health Products and Food Branch	02388006, 02388014, 02388022, 02434814
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	1130-MEE-0715, H45110513, H45130513, H5120513
EE	Ravimiamet	1593020, 1593042, 1593053, 1632800, 1632877, 1632888, 1632899, 1632901, 1632912, 1632923, 1632934, 1632945, 1666010, 1666021, 1666032, 1666043
ES	Centro de información online de medicamentos de la AEMPS	112773005, 112773008, 112773011, 112773015
FI	Lääkealan turvallisuus- ja kehittämiskeskus	106390, 461113, 488468, 553720
FR	Base de données publique des médicaments	60672974, 65291824, 65584250, 66180136
GB	Medicines & Healthcare Products Regulatory Agency	229518, 229748, 229750, 295076
HK	Department of Health Drug Office	61972, 61973, 61974, 66148
IE	Health Products Regulatory Authority	88170, 88182, 88279, 88289
IL	מִשְׂרַד הַבְּרִיאוּת	7170, 7171, 7172, 8088
JP	医薬品医療機器総合機構	4291034F1029, 4291034F2025
LT	Valstybinė vaistų kontrolės tarnyba	1071542, 1071543, 1071544, 1071545, 1071546, 1071547, 1071548, 1071549, 1071550, 1076654, 1076655, 1076656
NL	Z-Index G-Standaard, PRK	108464, 108472, 108480, 150843
NZ	Medicines and Medical Devices Safety Authority	16260, 16261, 16262, 19243
PL	Rejestru Produktów Leczniczych	100283673, 100283680, 100283696, 100329688
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64593001, W64594001, W64595001, W64596001
SG	Health Sciences Authority	14396P, 14397P, 14398P, 14927P
TN	Direction de la Pharmacie et du Médicament	10283361H, 10283362H, 10283363H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504012231, 8699504012248, 8699504012255, 8699504012262, 8699504013177, 8699504013184, 8699504013191, 8699504013207, 8699504013214, 8699504013221, 8699504013238
ZA	Health Products Regulatory Authority	48/34/0109, 48/34/0110, 48/34/0111